{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:33:26Z","timestamp":1789133606220,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s12325-024-02812-1","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T19:02:12Z","timestamp":1709665332000},"page":"1672-1684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Satisfaction with the Injection Experience of a New, Citrate-Free Formulation of Ixekizumab"],"prefix":"10.1007","volume":"41","author":[{"given":"Sanjay","family":"Chabra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Birt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bolce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William N.","family":"Malatestinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Kimel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Stefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Chad","family":"Cragun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"issue":"4","key":"2812_CR1","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2812_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019;71(1):5\u201332.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"2812_CR3","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599\u2013613.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"2812_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.berh.2018.10.006","volume":"32","author":"C L\u00f3pez-Medina","year":"2018","unstructured":"L\u00f3pez-Medina C, Molt\u00f3 A. Update on the epidemiology, risk factors, and disease outcomes of axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2018;32(2):241\u201353.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2812_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.","journal-title":"BMJ"},{"issue":"1","key":"2812_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-65.e19.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2812_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","volume":"14","author":"T Gudu","year":"2018","unstructured":"Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(5):405\u201317.","journal-title":"Expert Rev Clin Immunol"},{"key":"2812_CR8","unstructured":"Mayo Clinic. Ankylosing spondylitis. 2021. https:\/\/www.mayoclinic.org\/diseases-conditions\/ankylosing-spondylitis\/symptoms-causes\/syc-20354808. Accessed 22 Aug 2022."},{"issue":"2","key":"2812_CR9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","volume":"76","author":"AW Armstrong","year":"2017","unstructured":"Armstrong AW, Siegel MP, Bagel J, et al. From the medical board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"2812_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/JIR.S100940","volume":"9","author":"L Liu","year":"2016","unstructured":"Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39\u201350.","journal-title":"J Inflamm Res"},{"key":"2812_CR11","unstructured":"US FDA. FDA approves new psoriasis drug Taltz 2016. https:\/\/cacmap.fda.gov\/news-events\/press-announcements\/fda-approves-new-psoriasis-drug-taltz. Accessed 22 Aug 2023."},{"key":"2812_CR12","unstructured":"TALTZ (ixekizumab) injection, for subcutaneous use. Summary of Product Characteristics 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125521s014lbl.pdf. Accessed 22 Aug 2023."},{"issue":"4","key":"2812_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, et al. Phase\u00a03 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345\u201356.","journal-title":"N Engl J Med"},{"issue":"5","key":"2812_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/jamadermatol.2022.0655","volume":"158","author":"AS Paller","year":"2022","unstructured":"Paller AS, Seyger MMB, Magari\u00f1os GA, et al. Long-term efficacy and safety of up to 108\u00a0weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial. JAMA Dermatol. 2022;158(5):533\u201341.","journal-title":"JAMA Dermatol"},{"key":"2812_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jdin.2022.10.006","volume":"10","author":"YK Jang","year":"2023","unstructured":"Jang YK, Shin JU, Lee HJ, Yoon MS, Kim DH. Injection site reactions due to the use of biologics in patients with psoriasis: a retrospective study. JAAD Int. 2023;10:36\u20138.","journal-title":"JAAD Int"},{"issue":"6","key":"2812_CR16","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/jdv.16073","volume":"34","author":"ND Loft","year":"2020","unstructured":"Loft ND, Vaengebjerg S, Halling AS, Skov L, Egeberg A. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase\u00a0III studies. J Eur Acad Dermatol Venereol. 2020;34(6):1151\u201360.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"21","key":"2812_CR17","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1523\/JNEUROSCI.2087-20.2021","volume":"41","author":"YL Yang","year":"2021","unstructured":"Yang YL, Lai TW. Citric acid in drug formulations causes pain by potentiating acid-sensing ion channel 1. J Neurosci. 2021;41(21):4596\u2013606.","journal-title":"J Neurosci"},{"issue":"2","key":"2812_CR18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1742-7843.2006.pto_271.x","volume":"98","author":"T Laursen","year":"2006","unstructured":"Laursen T, Hansen B, Fisker S. Pain perception after subcutaneous injections of media containing different buffers. Basic Clin Pharmacol Toxicol. 2006;98(2):218\u201321.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"2812_CR19","first-page":"200","volume":"17","author":"NH Shear","year":"2018","unstructured":"Shear NH, Paul C, Blauvelt A, et al. Safety and tolerability of ixekizumab: integrated analysis of injection-site reactions from 11 clinical trials. J Drugs Dermatol. 2018;17(2):200\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"2812_CR20","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1007\/s12325-022-02126-0","volume":"39","author":"S Chabra","year":"2022","unstructured":"Chabra S, Gill BJ, Gallo G, et al. Ixekizumab citrate-free formulation: results from two clinical trials. Adv Ther. 2022;39(6):2862\u201372.","journal-title":"Adv Ther"},{"issue":"9","key":"2812_CR21","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1007\/s13300-021-01097-9","volume":"12","author":"KS Boye","year":"2021","unstructured":"Boye KS, Jordan JB, Malik RE, Currie BM, Matza LS. Patient perceptions of and preferences between characteristics of injectable diabetes treatments. Diabetes Ther. 2021;12(9):2387\u2013403.","journal-title":"Diabetes Ther"},{"issue":"6","key":"2812_CR22","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2337\/diacare.23.6.765","volume":"23","author":"ED Mollema","year":"2000","unstructured":"Mollema ED, Snoek FJ, Pouwer F, Heine RJ, van der Ploeg HM. Diabetes fear of injecting and self-testing questionnaire: a psychometric evaluation. Diabetes Care. 2000;23(6):765\u20139.","journal-title":"Diabetes Care"},{"issue":"3","key":"2812_CR23","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/rheumatology\/keu358","volume":"54","author":"J Bluett","year":"2015","unstructured":"Bluett J, Morgan C, Thurston L, et al. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology (Oxford). 2015;54(3):494\u20139.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02812-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02812-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02812-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T09:36:29Z","timestamp":1711186589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02812-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2812"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02812-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"28 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Julie Birt, Rebecca Bolce, Jeffrey Lisse, William N. Malatestinic, and Baojin Zhu are employees of Eli Lilly and Company and hold stock in the company. Sanjay Chabra has served as speaker for Eli Lilly and Company. W. Chad\u00a0Cragun has served as advisor and speaker for Eli Lilly and Company. Miriam Kimel, Julie McCormack, and Marissa Stefan are employees of Evidera Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the ethical principles based on the Declaration of Helsinki and was approved by an institutional review board (Advarra CIRBITM; Pro00065375) on 05 August 2022. All participants provided informed consent electronically.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}